Skip to main content
. 2023 Jun 20;26(6):e26104. doi: 10.1002/jia2.26104

Figure 3.

Figure 3

Adjusted odds ratios describing the association of mortality with a person's HIV characteristics, vaccination, demographic characteristics and co‐existing conditions, for adults with HIV and SARS‐CoV‐2 infections aged ≥ 40 years in the Western Cape. p‐Values are reported on the right. † Among those with evidence of ART at any time. ‡ The highest level of protection from among: No vaccine received (“None”); <28 days since a first vaccine dose (“Early”); ≥28 days since one dose of a Pfizer vaccine (“1 vaccine (P)”); ≥28 days since one Janssen vaccine, possibly with a second vaccine too, or ≥14 days since a second Pfizer vaccine (combined into the “primary” series due to the small sample). § Time since the most recent evidence of a start of an episode; with episodes beginning after 2 months before the SARS‐CoV‐2 diagnosis considered as ongoing.  Hypertension, diabetes, chronic obstructive pulmonary disease, chronic kidney disease and tuberculosis (at any time). Abbreviations: ART, antiretroviral therapy; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease.